Menu Search
Equities

Gensight Biologics SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0RIM:LSE

Gensight Biologics SA

Actions
  • Price (EUR)0.0818
  • Today's Change-0.001 / -0.61%
  • Shares traded374.19k
  • 1 Year change-73.05%
  • Beta0.3280
Data delayed at least 20 minutes, as of Feb 10 2026 14:04 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Gensight Biologics SA is a France-based biopharmaceutical company. The Company develops and commercializes gene therapy-based treatments of retinal degenerative diseases. It develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The Company intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

  • Revenue in EUR (TTM)194.00k
  • Net income in EUR-15.12m
  • Incorporated2012
  • Employees13.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.